Adriana Rossi, MD
Disclosures
Rossi reports consulting for Bristol-Myers Squibb, Caribou Biosciences, Janssen Pharmaceuticals, Karyopharm and Sanofi-Aventis.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Given that my focus is in CAR-T cells, I would say probably the most exciting thing are these novel, CAR-Ts, these so-called in vivo CARs, where we may be able to bypass using lymphodepletion or, you know, old school chemotherapy of any kind. And I think as most of my patients who undergo a CAR-T say that is the kind of therapy they would want again should they need another. And if we're going to use, multiple CARs, I think the limitation is really the lymphodepletion. So ideally, if we get to a place where we have in vivo CARs that are developed within the patient as far as timeline, as far as toxicity, and now, time will tell if efficacy will also, be maintained, so very promising and exciting results.
